menu
    • menu

    Company profile for XOMA

    NEW Drugs in Dev: 9
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Compa...
    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    XOMAUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2200 Powell Street, Suite 310 Emeryville, CA 94608 (510) 204-7200
    Telephone
    Telephone
    (510) 204-7200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.xoma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/xoma/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/xomacorp

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Village de la Chimie

    Not Confirmed

    envelop Contact Supplier

    Village de la Chimie

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XOMA Royalty Announces CFO Transition
    XOMA Royalty Announces CFO Transition

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216767/7281/en/XOMA-Royalty-Announces-CFO-Transition.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    XOMA Royalty, Takeda Strike Mezagitamab Royalty Deal
    XOMA Royalty, Takeda Strike Mezagitamab Royalty Deal

    30 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/30/3211329/7281/en/XOMA-Royalty-and-Takeda-Execute-Strategic-Royalty-Sharing-Transaction-and-Amend-Existing-Agreement-for-Mezagitamab.html

    GLOBENEWSWIRE
    30 Dec 2025
    Share Share
    XOMA Royalty Enters Into Agreement To Acquire Generation Bio
    XOMA Royalty Enters Into Agreement To Acquire Generation Bio

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205887/0/en/XOMA-Royalty-Enters-into-Agreement-to-Acquire-Generation-Bio.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    XOMA Royalty Completes Acquisition Of Mural Oncology
    XOMA Royalty Completes Acquisition Of Mural Oncology

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200742/7281/en/XOMA-Royalty-Announces-Closing-of-Transaction-to-Acquire-Mural-Oncology-plc.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    XOMA Royalty Reveals 2025 Q3 Financials & Business Milestones
    XOMA Royalty Reveals 2025 Q3 Financials & Business Milestones

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186116/7281/en/XOMA-Royalty-Reports-Third-Quarter-and-Year-to-Date-2025-Financial-Results-and-Highlights-Recent-Business-Achievements.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Xoma And Lava Buyout Cools With Lower Offer
    Xoma And Lava Buyout Cools With Lower Offer

    17 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/xoma-and-lava-cool-buyout-lowering-both-cash-offer-and-closing-conditions

    FIERCE BIOTECH
    17 Oct 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    XOMA Royalty Completes Acquisition of Generation Bio, Inc.

    Details:

    This drug candidate is currently being evaluated in Preclinical clinical studies for the treatment of hemophilia a.


    Lead Product(s): Undisclosed

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Oligonucleotide

    Recipient: Generation Bio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition February 09, 2026

    blank

    01

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Recipient : Generation Bio

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    XOMA Royalty Completes Acquisition of Generation Bio, Inc.

    Details : This drug candidate is currently being evaluated in Preclinical clinical studies for the treatment of hemophilia a.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    February 09, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xoma and Takeda Amend Agreement for Mezagitamab Royalty Sharing

    Details:

    The collaboration aims to advance Mezagitamab, an unconjugated antibody targeting lymphocyte differentiation antigen CD38, for Immune Thrombocytopenic Purpura.


    Lead Product(s): Mezagitamab

    Therapeutic Area: Immunology Brand Name: TAK-079

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Takeda Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 30, 2025

    blank

    02

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mezagitamab

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Takeda Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Xoma and Takeda Amend Agreement for Mezagitamab Royalty Sharing

    Details : The collaboration aims to advance Mezagitamab, an unconjugated antibody targeting lymphocyte differentiation antigen CD38, for Immune Thrombocytopenic Purpura.

    Product Name : TAK-079

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    December 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xoma Royalty to Acquire Generation Bio

    Details:

    Through the acquisition of an undisclosed oligonucleotide product, the deal aims to advance treatments for Hemophilia A.


    Lead Product(s): Undisclosed

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Oligonucleotide

    Recipient: Generation Bio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition December 15, 2025

    blank

    03

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Recipient : Generation Bio

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Xoma Royalty to Acquire Generation Bio

    Details : Through the acquisition of an undisclosed oligonucleotide product, the deal aims to advance treatments for Hemophilia A.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    December 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    XOMA Royalty Completes Acquisition of Mural Oncology plc

    Details:

    Through the acquisition of MURA-8518, a protein targeting IL-18 receptor, the deal aims to advance oncology research.


    Lead Product(s): MURA-8518,Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Protein

    Recipient: Mural Oncology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition December 05, 2025

    blank

    04

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MURA-8518,Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Mural Oncology

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    XOMA Royalty Completes Acquisition of Mural Oncology plc

    Details : Through the acquisition of MURA-8518, a protein targeting IL-18 receptor, the deal aims to advance oncology research.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Undisclosed

    December 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Xoma Royalty Completes Acquisition of LAVA Therapeutics N.V.

    Details:

    Under the acquisition of JNJ-89853413, an antibody targeting CD33, the deal aims to advance oncology research.


    Lead Product(s): JNJ-89853413

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Recipient: Lava Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition November 21, 2025

    blank

    05

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : JNJ-89853413

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Lava Therapeutics

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Xoma Royalty Completes Acquisition of LAVA Therapeutics N.V.

    Details : Under the acquisition of JNJ-89853413, an antibody targeting CD33, the deal aims to advance oncology research.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    November 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp

    Details:

    XOMA intends to redeploy, monetize, or otherwise dispose of nearly all of Mural’s assets, including its clinical and preclinical programs, including MURA-8518, a binding protein-resistant IL-18.


    Lead Product(s): MURA-8518

    Therapeutic Area: Oncology Brand Name: MURA-8518

    Study Phase: PreclinicalProduct Type: Protein

    Recipient: Mural Oncology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition August 20, 2025

    blank

    06

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MURA-8518

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Mural Oncology

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp

    Details : XOMA intends to redeploy, monetize, or otherwise dispose of nearly all of Mural’s assets, including its clinical and preclinical programs, including MURA-8518, a binding protein-resistant IL-18.

    Product Name : MURA-8518

    Product Type : Protein

    Upfront Cash : Undisclosed

    August 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics

    Details:

    XOMA Royalty is acquiring economic interests, royalties and milestones, from LAVA Therapeutics' drug development programs, JNJ-89853413, targeting CD33 and PF-08046052, targeting EGFR.


    Lead Product(s): JNJ-89853413

    Therapeutic Area: Oncology Brand Name: JNJ-89853413

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Recipient: Lava Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition August 04, 2025

    blank

    07

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : JNJ-89853413

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Lava Therapeutics

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics

    Details : XOMA Royalty is acquiring economic interests, royalties and milestones, from LAVA Therapeutics' drug development programs, JNJ-89853413, targeting CD33 and PF-08046052, targeting EGFR.

    Product Name : JNJ-89853413

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    August 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA

    Details:

    Through acquisition, HIL-214, a VLP based vaccine candidate and related norovirus vaccine programs are explicitly included in the contingent value rights.


    Lead Product(s): HIL-214

    Therapeutic Area: Infections and Infectious Diseases Brand Name: HIL-214

    Study Phase: Phase I/ Phase IIProduct Type: Vaccine

    Recipient: HilleVax

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition August 04, 2025

    blank

    08

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HIL-214

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I/ Phase II

    Recipient : HilleVax

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA

    Details : Through acquisition, HIL-214, a VLP based vaccine candidate and related norovirus vaccine programs are explicitly included in the contingent value rights.

    Product Name : HIL-214

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    August 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    XOMA Acquires Mezagitamab Royalties From BioInvent for Up to $30 Million

    Details:

    XOMA Royalty has purchased the future TAK-079 (mezagitamab), a fully human immunoglobulin IgG1 monoclonal antibody, royalty and milestone interests held by BioInvent.


    Lead Product(s): Mezagitamab

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Recipient: BioInvent

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Agreement May 27, 2025

    blank

    09

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mezagitamab

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Recipient : BioInvent

    Deal Size : $30.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    XOMA Acquires Mezagitamab Royalties From BioInvent for Up to $30 Million

    Details : XOMA Royalty has purchased the future TAK-079 (mezagitamab), a fully human immunoglobulin IgG1 monoclonal antibody, royalty and milestone interests held by BioInvent.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    May 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    XOMA Acquires Pulmokine for $20M Adding Seralutinib Phase 3 Royalty Interest

    Details:

    Through the acquisition, XOMA add GB002 (seralutinib), a potent PDGFR, colony stimulating factor 1 receptor, and c-KIT kinase inhibitor, Phase 3 asset being studied in pulmonary arterial hypertension.


    Lead Product(s): Seralutinib

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Recipient: Pulmokine

    Deal Size: $20.0 million Upfront Cash: $20.0 million

    Deal Type: Acquisition December 02, 2024

    blank

    10

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed

    XOMA

    U.S.A
    arrow
    Village de la Chimie
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Seralutinib

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Recipient : Pulmokine

    Deal Size : $20.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    XOMA Acquires Pulmokine for $20M Adding Seralutinib Phase 3 Royalty Interest

    Details : Through the acquisition, XOMA add GB002 (seralutinib), a potent PDGFR, colony stimulating factor 1 receptor, and c-KIT kinase inhibitor, Phase 3 asset being studied in pulmonary arterial hypertension.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : $20.0 million

    December 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact XOMA and get a quotation

    XOMA is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find a price of XOMA 3AB bulk offered by XOMA

    Find a price of CELL LINE (SOURCE, HISTORY AND GENERATION ) FOR SCH 900105 CONCENTRATE FOR INJECTION bulk offered by XOMA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search